Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Protalix BioTherapeutics, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
NYSE · Biological Products, (No Diagnostic Substances)
Prev close 2.67 · gapped above the open, then crossed back over prior close. High/low 2.72 at 10:30 am ET, 2.66 at 12:30 pm ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We have agreed to sell drug substance to Pfizer and Chiesi for the production of Elelyso and Elfabrio, respectively.”
FILING10-K0001104659-26-029858cik 0001006281
“We face the risk of lower than anticipated purchases of BioManguinhos alfataliglicerase by the Brazilian MoH.”
FILING10-K0001104659-26-029858cik 0001006281
“We have agreed to sell drug substance to Pfizer and Chiesi for the production of Elelyso and Elfabrio, respectively.”
FILING10-K0001104659-26-029858cik 0001006281
“Fiocruz has not complied with the purchase requirements of the Brazil Agreement in the past, and we expect Fiocruz will continue to not comply and may otherwise materially breach the agreement.”
FILING10-K0001104659-26-029858cik 0001006281
“Under the F/F Agreement, we agreed to supply Chiesi with drug substance for pegunigalsidase alfa and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for pegunigalsidase alfa, including to support the anticipated global launch of pegunigalsidase alfa.”
FILING10-K0001104659-26-029858cik 0001006281
“On February 27, 2023, we entered into that certain At The Market Offering Agreement, as may be amended from time to time, or the 2023 Sales Agreement, with H.C. Wainwright & Co., LLC, as our sales agent, or the Agent, for the sale of up to $20.0 million of our common stock from time to time .”
FILING10-K0001104659-26-029858cik 0001006281
“The FIH study was conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines.”
FILING10-K0001104659-26-029858cik 0001006281
“Secarna plans to apply OligoCreator ® , its proprietary AI-empowered oligonucleotide discovery and development platform, to design and profile ASO candidates against those targets.”
FILING10-K0001104659-26-029858cik 0001006281
Watchlist prices, news filtered to it, and its next report on your desk.
Protalix BioTherapeutics, Inc. has 4 disclosed suppliers and 4 disclosed customers. Each one is named in an SEC filing, either Protalix BioTherapeutics, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
PLX (Protalix BioTherapeutics, Inc.) has 4 disclosed suppliers and 4 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: PFE −0.67%, in healthcare.